valsartan has been researched along with Liver Dysfunction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alaaeldin, R; Attya, ME; Elhamadany, EY; Fathy, M; Mohyeldin, RH; Sharata, EE | 1 |
| Biegus, J; Ponikowski, P; Zymliński, R | 1 |
| Ayalasomayajula, S; Boggarapu, S; Langenickel, T; Pal, P; Sunkara, G | 1 |
| Chandra, P; Kulmatycki, KM; Langenickel, T; Lin, TH; Ng, WH; Pal, P; Rajman, I; Sunkara, G; Zhou, W | 1 |
| Ripley, TL | 1 |
| Benjamin, IS; Brookman, LJ; Flesch, G; Lloyd, P; Mullins, F; Palmer, KR; Rolan, PE; Sioufi, A; Waldmeier, F; Wyld, PJ | 1 |
2 review(s) available for valsartan and Liver Dysfunction
| Article | Year |
|---|---|
Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biphenyl Compounds; Drug Combinations; Drug Interactions; Heart Failure; Humans; Liver Diseases; Renal Insufficiency; Tetrazoles; Valsartan | 2017 |
Valsartan in chronic heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Drug Therapy, Combination; Female; Formularies, Hospital as Topic; Heart Failure; Humans; Liver Diseases; Male; Patient Education as Topic; Pregnancy; Randomized Controlled Trials as Topic; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2005 |
4 other study(ies) available for valsartan and Liver Dysfunction
| Article | Year |
|---|---|
LCZ696 attenuates sepsis-induced liver dysfunction in rats; the role of oxidative stress, apoptosis, and JNK1/2-P38 signaling pathways.
Topics: Animals; Apoptosis; Caspase 3; Interleukin-6; Liver Diseases; Oxidative Stress; Rats; Sepsis; Signal Transduction; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Valsartan | 2023 |
Looking at the heart failure through the prism of liver dysfunction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Liver Diseases; Prognosis; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.
Topics: Aminobutyrates; Area Under Curve; Biphenyl Compounds; Drug Combinations; Female; Healthy Volunteers; Humans; Liver; Liver Diseases; Male; Middle Aged; Tetrazoles; Valsartan | 2017 |
Pharmacokinetics of valsartan in patients with liver disease.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Bile; Biotransformation; Drainage; Female; Humans; Injections, Intravenous; Liver Diseases; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1997 |